Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2024-04-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
独立董事工作细则
Governance Information Classification · 95% confidence The document is titled '东北制药集团股份有限公司 独立董事工作细则' which translates to 'Northeast Pharmaceutical Group Co., Ltd. Independent Director Work Rules'. The content details the governance structure, duties, qualifications, appointment, and responsibilities of independent directors within the company. It references relevant laws, regulations, and stock exchange rules, and outlines internal governance practices related to independent directors. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal rules document, focusing on board structure and governance practices. Therefore, it fits the category of Governance Information (CGR). The document length (6124 characters) and detailed content support this classification with high confidence.
2024-04-25 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Work Rules of the Remuneration and Assessment Committee of the Board of Directors" of Dongbei Pharmaceutical Group Co., Ltd. It details the structure, responsibilities, composition, and procedures of the Remuneration and Assessment Committee, which is a specialized committee of the board. The content focuses on governance practices related to board and senior management remuneration and assessment policies, committee meeting rules, and related governance procedures. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no earnings information. The document is a governance-related internal rules document about the board committee's operation and responsibilities. Therefore, it fits best under Governance Information (CGR). The document length is 2606 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2024-04-25 Chinese
关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程). It details changes in registered capital and disclosure media, approved by the board and pending shareholder approval. The document is short (1035 characters) and does not contain financial statements or detailed financial data. It is not a full report but an announcement of governance-related changes. Therefore, it fits best under Governance Information (CGR).
2024-04-25 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "东北制药集团股份有限公司2024年第一季度报告" which translates to "Northeast Pharmaceutical Group Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial metrics for the first quarter of 2024. The document explicitly states it is a quarterly report and mentions it is unaudited. The length is substantial (over 11,000 characters) and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is an announcement or a certification only, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 26th meeting of the 9th Board of Directors of Northeast Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and references other documents published on the same day. The content focuses on board meeting decisions, including approval of the 2024 Q1 report, amendments to company bylaws, and preparations for a shareholders' meeting. There is no detailed financial data or full report content here, only the announcement of board resolutions and voting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-04-25 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled '东北制药集团股份有限公司 董事会议事规则' which translates to 'Northeast Pharmaceutical Group Co., Ltd. Board Meeting Rules'. It details the rules and procedures for the company's board of directors meetings, including their powers, meeting notification procedures, voting, and the role of independent directors. There is no financial data, earnings information, or regulatory filings related to financial results. Instead, it is a governance document outlining internal board governance practices and rules. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is about 5110 characters, sufficient for a detailed governance report rather than a brief announcement or notice.
2024-04-25 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.